Circ: Heart Failure

Structural racism drives disparities in advanced HF care. New state-of-the-art review in Circ:HF outlines solutions. #HF #Statistics #Access ahajrnls.org/4nrCUl4

Tolerogenic dendritic cells may help sustain pediatric heart transplant tolerance by suppressing alloreactive T-cells via TGF-β ahajrnls.org/4fqiVBg

Bile Acids, Mitochondria, and Myocardial Stiffness: A Shared Mechanism in Fontan Circulation and Metabolic Dysfunction-Associated Steatotic Liver Disease @sasha_opo @RichKrasuskiMD @AshishHShah3 ahajrnls.org/4uGTRKL

A roadmap for gene therapy in inherited cardiomyopathy: delivery platforms, genome editing, targets, and trials @radhikawal @MGBResearchNews ahajrnls.org/48RvWjy

How trustworthy AI and big data are shaping the future of heart failure care: opportunities and challenges @mamouei @fwasselbergs ahajrnls.org/433u17X

CardioTTRansform baseline characteristics presented at #HeartFailure26! Great work as usual by @MathewMaurer @escardio Largest trial in ATTR CM with widespread use of stabilizers and more SGLT2i than other studies. Comparison with other trials seen in the tagged pictures. We appear to have a cohort more similar to ATTRIBUTE CM in disease severity. HELIOS B still has the healthiest population. Copublished in @CircHF

Rationale and Design of CARDIO-TTRansform, a Phase 3 Trial of Eplontersen in Transthyretin Amyloid Cardiomyopathy CARDIO-TTRansform is fully enrolled, with 1432 randomized participants who were dosed with study drug or placebo. As the largest transthyretin amyloidosis with cardiomyopathy study to date, it will evaluate whether eplontersen improves cardiovascular outcomes in patients receiving locally available standard of care, including TTR stabilizers. @MasriAhmadMD @CircHF @CircAHA @gcfmd @SJGreene_md @AndrewJSauer ahajournals.org/doi/10.1161/CI…

Simultaneous Publication w/ #HeartFailure26 by Gunnthorsdottir et al in @CircHF: 📝Medication adherence in HF is shaped by routines, diuretic burden, psychosocial needs, and care continuity, not motivation alone. ➡️ahajournals.org/doi/10.1161/CI… @AHAScience

Simultaneous Publication w/ #HeartFailure26 by Maurer et al in @CircHF: 📝CARDIO-TTRansform is designed to evaluate whether eplontersen improves cardiovascular outcomes in patients with ATTR-CM ➡️ahajournals.org/doi/10.1161/CI… @AHAScience

Myosin ATPase Inhibition Relieves the Energetic Burden in Skeletal Myofibres of Patients With Heart Failure With Reduced Ejection Fraction @hbotker @LabBowen ahajrnls.org/42sHiXw

Vasoactive treatment in cardiogenic shock varies widely across CICUs, driven by patient-level factors and institutional practice patterns @TIMIStudyGroup @DrRobRoswell @ICUDocAP @TIMIStudyGroup ahajournals.org/doi/10.1161/CI…

Sacubitril/valsartan lowers BP; ANP drives early effects, while bradykinin contributes modestly during chronic HF therapy @adina_turcu @vumchealth ahajrnls.org/4t50eGL

Simultaneous Publication in @CircHF w/ #ISHLT2026 from @lucabaldetti et al 📝 Circulatory Support Escalation in Cardiogenic Shock Outcomes & Predictors of Successful Escalation from an Int'l, Multi-Center Cardiac Intensive Care Registry ahajournals.org/doi/10.1161/CI… @AHAScience

Hemodynamic Impact of Ventricular Tachycardia: Insights from Pressure-Volume Loop Monitoring @GiulioMonde @ToineEnden @drnvanmieghem ahajrnls.org/42qUAUk

Over 20 years, GWTG-HF has shown sustained improvements in quality of care for patients hospitalized with heart failure @kofi_larry @NMHHeartdoc @SJGreene_md @docsabe @zhaojuanwendy @GCFMD ahajrnls.org/48ccU7a

New understanding of heart failure pathophysiology through unbiased large-scale peptidomics analysis @AdriaanVoors ahajrnls.org/4vG333q

Phenomapping of Heart Failure Patients: All Clusters Are Wrong, But Are They Useful? ahajrnls.org/4cpMxMa

Device-Related Adverse Events and Outcomes in Patients With Temporary Mechanical Circulatory Support Placed at Referral Centers Versus Cardiogenic Shock Hub Centers: An Observational Analysis @RyanTedfordMD @Brian_Houston12 @HajjJennifer @tmcsbird ahajrnls.org/4dKKq81

Mavacamten and septal ablation unload the heart in obstructive HCM and may reduce myocardial workload and energetic cost @ChristophMaack ahajrnls.org/4t7A5HX

Delivery Is Not the Finish Line: Critical Transition of Care in the Fourth Trimester ahajrnls.org/4vuYEQF